Cargando…
Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study
BACKGROUND: Treatment options for patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC) are not clear after progression on previous treatment with PD-(L)1 inhibitor; critical gaps in evidence remain for such cases. Immunotherapy combined with antiangiogenic therapy has been reported t...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319986/ https://www.ncbi.nlm.nih.gov/pubmed/37415845 http://dx.doi.org/10.1016/j.eclinm.2023.102043 |
_version_ | 1785068352797933568 |
---|---|
author | Ding, Xi Hua, Yi-Jun Zou, Xiong Chen, Xiao-Zhong Zhang, Xi-Mei Xu, Bei Ouyang, Yan-Feng Tu, Zi-Wei Li, Hui-Feng Duan, Chong-Yang Zhang, Wei-Jing You, Rui Liu, You-Ping Liu, Yong-Long Yang, Qi Huang, Pei-Yu Wang, Shu-Ni Fan, Jia Chen, Ming-Yuan |
author_facet | Ding, Xi Hua, Yi-Jun Zou, Xiong Chen, Xiao-Zhong Zhang, Xi-Mei Xu, Bei Ouyang, Yan-Feng Tu, Zi-Wei Li, Hui-Feng Duan, Chong-Yang Zhang, Wei-Jing You, Rui Liu, You-Ping Liu, Yong-Long Yang, Qi Huang, Pei-Yu Wang, Shu-Ni Fan, Jia Chen, Ming-Yuan |
author_sort | Ding, Xi |
collection | PubMed |
description | BACKGROUND: Treatment options for patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC) are not clear after progression on previous treatment with PD-(L)1 inhibitor; critical gaps in evidence remain for such cases. Immunotherapy combined with antiangiogenic therapy has been reported to have synergistic antitumor activity. Therefore, we evaluated the efficacy and safety of camrelizumab plus famitinib in patients with RM-NPC who failed treatment with PD-1 inhibitor-containing regimens. METHODS: This multicenter, adaptive Simon minimax two-stage, phase II study enrolled patients with RM-NPC refractory to at least one line of systemic platinum-containing chemotherapy and anti-PD-(L)1 immunotherapy. The patient received camrelizumab 200 mg every 3 weeks and famitinib 20 mg once per day. The primary endpoint was objective response rate (ORR), and the study could be stopped early as criterion for efficacy was met (>5 responses). Key secondary endpoints included time to response (TTR), disease control rate (DCR), progression-free survival (PFS), duration of response (DoR), overall survival (OS), and safety. This trial was registered with ClinicalTrials.gov, NCT04346381. FINDINGS: Between October 12, 2020, and December 6, 2021, a total of 18 patients were enrolled since six responses were observed. The ORR was 33.3% (90% CI, 15.6–55.4) and the DCR was 77.8% (90% CI, 56.1–92.0). The median TTR was 2.1 months, the median DoR was 4.2 months (90% CI, 3.0–not reach), and the median PFS was 7.2 months (90% CI, 4.4–13.3), with a median follow-up duration of 16.7 months. Treatment-related adverse events (TRAEs) of grade ≥3 were reported in eight (44.4%) patients, with the most common being decreased platelet count and/or neutropenia (n = 4, 22.2%). Treatment-related serious AEs occurred in six (33.3%) patients, and no deaths occurred due to TRAEs. Four patients developed grade ≥3 nasopharyngeal necrosis; two of them developed grade 3–4 major epistaxis, and they were cured by nasal packing and vascular embolization. INTERPRETATION: Camrelizumab plus famitinib exhibited encouraging efficacy and tolerable safety profiles in patients with RM-NPC who failed frontline immunotherapy. Further studies are needed to confirm and expand these findings. FUNDING: 10.13039/100018731Jiangsu Hengrui Pharmaceutical Co., Ltd. |
format | Online Article Text |
id | pubmed-10319986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-103199862023-07-06 Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study Ding, Xi Hua, Yi-Jun Zou, Xiong Chen, Xiao-Zhong Zhang, Xi-Mei Xu, Bei Ouyang, Yan-Feng Tu, Zi-Wei Li, Hui-Feng Duan, Chong-Yang Zhang, Wei-Jing You, Rui Liu, You-Ping Liu, Yong-Long Yang, Qi Huang, Pei-Yu Wang, Shu-Ni Fan, Jia Chen, Ming-Yuan eClinicalMedicine Articles BACKGROUND: Treatment options for patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC) are not clear after progression on previous treatment with PD-(L)1 inhibitor; critical gaps in evidence remain for such cases. Immunotherapy combined with antiangiogenic therapy has been reported to have synergistic antitumor activity. Therefore, we evaluated the efficacy and safety of camrelizumab plus famitinib in patients with RM-NPC who failed treatment with PD-1 inhibitor-containing regimens. METHODS: This multicenter, adaptive Simon minimax two-stage, phase II study enrolled patients with RM-NPC refractory to at least one line of systemic platinum-containing chemotherapy and anti-PD-(L)1 immunotherapy. The patient received camrelizumab 200 mg every 3 weeks and famitinib 20 mg once per day. The primary endpoint was objective response rate (ORR), and the study could be stopped early as criterion for efficacy was met (>5 responses). Key secondary endpoints included time to response (TTR), disease control rate (DCR), progression-free survival (PFS), duration of response (DoR), overall survival (OS), and safety. This trial was registered with ClinicalTrials.gov, NCT04346381. FINDINGS: Between October 12, 2020, and December 6, 2021, a total of 18 patients were enrolled since six responses were observed. The ORR was 33.3% (90% CI, 15.6–55.4) and the DCR was 77.8% (90% CI, 56.1–92.0). The median TTR was 2.1 months, the median DoR was 4.2 months (90% CI, 3.0–not reach), and the median PFS was 7.2 months (90% CI, 4.4–13.3), with a median follow-up duration of 16.7 months. Treatment-related adverse events (TRAEs) of grade ≥3 were reported in eight (44.4%) patients, with the most common being decreased platelet count and/or neutropenia (n = 4, 22.2%). Treatment-related serious AEs occurred in six (33.3%) patients, and no deaths occurred due to TRAEs. Four patients developed grade ≥3 nasopharyngeal necrosis; two of them developed grade 3–4 major epistaxis, and they were cured by nasal packing and vascular embolization. INTERPRETATION: Camrelizumab plus famitinib exhibited encouraging efficacy and tolerable safety profiles in patients with RM-NPC who failed frontline immunotherapy. Further studies are needed to confirm and expand these findings. FUNDING: 10.13039/100018731Jiangsu Hengrui Pharmaceutical Co., Ltd. Elsevier 2023-06-23 /pmc/articles/PMC10319986/ /pubmed/37415845 http://dx.doi.org/10.1016/j.eclinm.2023.102043 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Articles Ding, Xi Hua, Yi-Jun Zou, Xiong Chen, Xiao-Zhong Zhang, Xi-Mei Xu, Bei Ouyang, Yan-Feng Tu, Zi-Wei Li, Hui-Feng Duan, Chong-Yang Zhang, Wei-Jing You, Rui Liu, You-Ping Liu, Yong-Long Yang, Qi Huang, Pei-Yu Wang, Shu-Ni Fan, Jia Chen, Ming-Yuan Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study |
title | Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study |
title_full | Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study |
title_fullStr | Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study |
title_full_unstemmed | Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study |
title_short | Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study |
title_sort | camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with pd-1 blockade: data from a multicohort phase 2 study |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319986/ https://www.ncbi.nlm.nih.gov/pubmed/37415845 http://dx.doi.org/10.1016/j.eclinm.2023.102043 |
work_keys_str_mv | AT dingxi camrelizumabplusfamitinibinpatientswithrecurrentormetastaticnasopharyngealcarcinomatreatedwithpd1blockadedatafromamulticohortphase2study AT huayijun camrelizumabplusfamitinibinpatientswithrecurrentormetastaticnasopharyngealcarcinomatreatedwithpd1blockadedatafromamulticohortphase2study AT zouxiong camrelizumabplusfamitinibinpatientswithrecurrentormetastaticnasopharyngealcarcinomatreatedwithpd1blockadedatafromamulticohortphase2study AT chenxiaozhong camrelizumabplusfamitinibinpatientswithrecurrentormetastaticnasopharyngealcarcinomatreatedwithpd1blockadedatafromamulticohortphase2study AT zhangximei camrelizumabplusfamitinibinpatientswithrecurrentormetastaticnasopharyngealcarcinomatreatedwithpd1blockadedatafromamulticohortphase2study AT xubei camrelizumabplusfamitinibinpatientswithrecurrentormetastaticnasopharyngealcarcinomatreatedwithpd1blockadedatafromamulticohortphase2study AT ouyangyanfeng camrelizumabplusfamitinibinpatientswithrecurrentormetastaticnasopharyngealcarcinomatreatedwithpd1blockadedatafromamulticohortphase2study AT tuziwei camrelizumabplusfamitinibinpatientswithrecurrentormetastaticnasopharyngealcarcinomatreatedwithpd1blockadedatafromamulticohortphase2study AT lihuifeng camrelizumabplusfamitinibinpatientswithrecurrentormetastaticnasopharyngealcarcinomatreatedwithpd1blockadedatafromamulticohortphase2study AT duanchongyang camrelizumabplusfamitinibinpatientswithrecurrentormetastaticnasopharyngealcarcinomatreatedwithpd1blockadedatafromamulticohortphase2study AT zhangweijing camrelizumabplusfamitinibinpatientswithrecurrentormetastaticnasopharyngealcarcinomatreatedwithpd1blockadedatafromamulticohortphase2study AT yourui camrelizumabplusfamitinibinpatientswithrecurrentormetastaticnasopharyngealcarcinomatreatedwithpd1blockadedatafromamulticohortphase2study AT liuyouping camrelizumabplusfamitinibinpatientswithrecurrentormetastaticnasopharyngealcarcinomatreatedwithpd1blockadedatafromamulticohortphase2study AT liuyonglong camrelizumabplusfamitinibinpatientswithrecurrentormetastaticnasopharyngealcarcinomatreatedwithpd1blockadedatafromamulticohortphase2study AT yangqi camrelizumabplusfamitinibinpatientswithrecurrentormetastaticnasopharyngealcarcinomatreatedwithpd1blockadedatafromamulticohortphase2study AT huangpeiyu camrelizumabplusfamitinibinpatientswithrecurrentormetastaticnasopharyngealcarcinomatreatedwithpd1blockadedatafromamulticohortphase2study AT wangshuni camrelizumabplusfamitinibinpatientswithrecurrentormetastaticnasopharyngealcarcinomatreatedwithpd1blockadedatafromamulticohortphase2study AT fanjia camrelizumabplusfamitinibinpatientswithrecurrentormetastaticnasopharyngealcarcinomatreatedwithpd1blockadedatafromamulticohortphase2study AT chenmingyuan camrelizumabplusfamitinibinpatientswithrecurrentormetastaticnasopharyngealcarcinomatreatedwithpd1blockadedatafromamulticohortphase2study |